LY6D

Across TCGA pan-cancer cohorts, LY6D Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated LY6D data layer compared with 22 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher LY6D Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated LY6D expression acts as an unfavorable survival marker.

LUSC, SKCM, and PRAD are the cancer types where LY6D Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUSC	OS	Median	All	0.181	0.762	.005	18	view →
SKCM	OS	Median	All	0.174	0.781	<.001	15	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

LY6D–LUSC (OS)

Open the LUSC breakdown →